The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax
In this video, Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses the results of a multicenter study which investigated the long-term survival of patients with acute myeloid leukemia (AML) who discontinued treatment with azacitidine and venetoclax due to poor tolerance. Dr Garciaz further comments on the possibility of implementing treatment-free intervals in this patient population. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
